Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs 675

Quick answer

Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Pipeline programs

Page 9 of 15

  1. Rimonabant

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  2. Risperidone

    Indivior Pty Ltd

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  3. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  4. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Severe Postpartum Depression

    phase 2 small molecule completed

    1 trial

  5. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 2 small molecule completed

    1 trial

  6. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  7. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  8. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  9. SK-PC-B70M

    Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  10. SNUBH-NM-333(18F)

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 other terminated

    1 trial

  11. SPD489 (lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia and Predominant Negative Symptoms

    phase 2 small molecule completed

    1 trial

  12. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  13. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  14. Sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  15. Sarcosine and D-serine

    Hospital Authority, Hong Kong

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  16. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  17. Solriamfetol

    Axsome Therapeutics

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  18. Soticlestat

    Takeda

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  19. TAK-041

    NEUROCRINE BIOSCIENCES INC

    Stable Schizophrenia

    phase 2 small molecule completed

    1 trial

  20. TAK-063 20 mg

    Takeda

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  21. TAK-071

    Takeda

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  22. TAK-653

    Takeda

    Treatment-Resistant Depression

    phase 2 small molecule terminated

    1 trial

  23. TAK-935

    Takeda

    Epilepsy

    phase 2 small molecule completed

    2 trials

  24. TMP-18122023-58

    Lacuna Pharma Pty Ltd

    Adults with ADHD and moderate to severe depression

    phase 2 small molecule active

    1 trial

  25. TNX-601 ER

    Tonix Pharmaceuticals Holding

    Depression

    phase 2 small molecule completed

    1 trial

  26. TPM XR

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule completed

    1 trial

  27. Talampanel

    Teva Pharma GmbH

    Epilepsy

    phase 2 small molecule completed

    1 trial

  28. TolDec

    The George Institute

    Multiple sclerosis

    phase 2 small molecule active

    1 trial

  29. UB-311

    United Therapeutics Europe Ltd

    Alzheimer's Disease

    phase 2 mab terminated

    3 trials

  30. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Remitting Multiple Sclerosis

    phase 2 mab completed

    1 trial

  31. Ublituximab

    TG THERAPEUTICS, INC.

    multiple sclerosis

    phase 2 small molecule active

    1 trial

  32. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Partial Epilepsy

    phase 2 small molecule completed

    1 trial

  33. VX-765 Part A

    Vertex Pharmaceuticals (Australia) Pty.

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  34. VY7523

    Voyager Therapeutics

    Alzheimer's Disease (AD)

    phase 2 small molecule active

    1 trial

  35. Venlafaxine

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  36. Vitamin D3

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 other completed

    1 trial

  37. WA39085

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis (RRMS)

    phase 2 small molecule active

    1 trial

  38. Wei Li Bai capsules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  39. XPF-008-201

    Xenon Pharmaceuticals

    Adult focal (partial onset) epilepsy

    phase 2 small molecule active

    1 trial

  40. ZB012-02-002

    Zenas BioPharma

    RELAPSING MULTIPLE SCLEROSIS

    phase 2 small molecule active

    1 trial

  41. [123I] 5-IA

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  42. [123I]B-CIT

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  43. [123I]β-CIT

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  44. [18F]PI-2620

    The George Institute

    Down Syndrome, Alzheimer disease

    phase 2 small molecule active

    1 trial

  45. [18F]PI-2620

    The George Institute

    Progressive supranuclear palsy, Parkinson's disease

    phase 2 small molecule active

    1 trial

  46. [18F]PI-2620

    The George Institute

    Down Syndrome., Alzheimer´s Disease.

    phase 2 small molecule active

    1 trial

  47. armodafinil

    Teva Pharma GmbH

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  48. ataluren

    PTC THERAPEUTICS, INC.

    Epilepsy

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

675 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.